• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ovarian Cancer - Pipeline Review, H2 2012 Product Image

Ovarian Cancer - Pipeline Review, H2 2012

  • ID: 2298830
  • October 2012
  • 449 pages
  • Global Markets Direct

Ovarian Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Ovarian Cancer.
- A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 15
List of Figures 21
Introduction 22
REPORT COVERAGE 22
Ovarian Cancer Overview 23
Therapeutics Development 24
An Overview of Pipeline Products for Ovarian Cancer 24
Ovarian Cancer Therapeutics under Development by Companies 26
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 38
Late Stage Products 49
Comparative Analysis 49
Mid Clinical Stage Products 50
Comparative Analysis 50
Early Clinical Stage Products 51
Comparative Analysis 51
Discovery and Pre-Clinical Stage Products 52
Comparative Analysis 52
Ovarian Cancer Therapeutics – Products under Development by Companies 53
Ovarian Cancer Therapeutics – Products under Investigation by Universities/Institutes 69
Companies Involved in Ovarian Cancer Therapeutics Development 97
Bristol-Myers Squibb Company 97
Johnson & Johnson 98
Boehringer Ingelheim GmbH 99
F. Hoffmann-La Roche Ltd. 100
Abbott Laboratories 101
AlphaRx, Inc. 102
Amgen Inc. 103
Sanofi-Aventis 104
AstraZeneca PLC 105
Eli Lilly and Company 106
Viralytics Ltd. 107
GlaxoSmithKline plc 108
Bioniche Life Sciences, Inc. 109
Tekmira Pharmaceuticals Corp. 110
Genentech, Inc. 111
Nektar Therapeutics 112
Bavarian Nordic A/S 113
Daiichi Sankyo Company, Ltd 114
Merck & Co., Inc. 115
AbGenomics International, Inc. 116
FASgen, Inc. 117
Oxford BioMedica plc 118
Generex Biotechnology Corporation 119
Amorfix Life Sciences Ltd. 120
MediGene AG 121
Prolexys Pharmaceuticals, Inc. 122
Aposense Ltd. 123
ZIOPHARM Oncology, Inc. 124
Millennium Pharmaceuticals, Inc. 125
Samyang Corporation 126
Aphios Corporation 127
Astellas Pharma Inc. 128
Eisai Co., Ltd. 129
ImmunoGen, Inc. 130
OSI Pharmaceuticals, Inc. 131
Sunesis Pharmaceuticals, Inc. 132
Cell Therapeutics, Inc. 133
Santaris Pharma A/S 134
Exelixis, Inc. 135
Menarini Group 136
Alfacell Corporation 137
Celgene Corporation 138
Onyx Pharmaceuticals, Inc. 139
Bayer AG 140
Merck KGaA 141
Access Pharmaceuticals, Inc. 142
Advaxis, Inc. 143
Neogenix Oncology Corporation 144
EntreMed, Inc. 145
Hana Biosciences, Inc. 146
Celldex Therapeutics, Inc. 147
ValiRx Plc 148
AEterna Zentaris Inc. 149
ImmunoCellular Therapeutics, Ltd. 150
Lorus Therapeutics Inc 151
Marshall Edwards, Inc. 152
AVAX Technologies, Inc. 153
Basilea Pharmaceutica Ltd. 154
Bionomics Limited 155
Novogen Limited 156
Cleveland BioLabs, Inc. 157
Oncolytics Biotech Inc. 158
OXiGENE, Inc. 159
Critical Outcome Technologies Inc. 160
ADVENTRX Pharmaceuticals 161
Allos Therapeutics, Inc 162
Alnylam Pharmaceuticals, Inc 163
Telik, Inc. 164
TopoTarget A/S 165
Poniard Pharmaceuticals, Inc. 166
Oncogenex Pharmaceuticals, Inc. 167
Dendreon Corporation 168
Prima BioMed Limited 169
Progen Pharmaceuticals Limited 170
TTY Biopharm Company Limited 171
Innocell Corporation 172
PharmaGap Inc. 173
Quest PharmaTech Inc. 174
Synta Pharmaceuticals Corp. 175
Oasmia Pharmaceutical AB 176
RXi Pharmaceuticals Corporation 177
Rexahn Pharmaceuticals, Inc. 178
MabVax Therapeutics, Inc. 179
Morphotek, Inc. 180
Cancer Research Technology Limited 181
Avanti Therapeutics 182
Chipscreen Biosciences Ltd 183
Supratek Pharma Inc. 184
GANYMED Pharmaceuticals AG 185
Nerviano Medical Sciences S.r.l. 186
Glycotope GmbH 187
TRION Pharma GmbH 188
BioNumerik Pharmaceuticals, Inc. 189
Cerulean Pharma, Inc. 190
Heat Biologics, Inc. 191
MacroGenics, Inc. 192
Boston Biomedical, Inc. 193
Azaya Therapeutics, Inc. 194
CanBas Co., Ltd. 195
Merrimack Pharmaceuticals, Inc. 196
Spirogen Ltd. 197
Neotropix, Inc. 198
Conatus Pharmaceuticals Inc. 199
CritiTech, Inc. 200
Deciphera Pharmaceuticals, LLC 201
BioCancell Therapeutics, Inc. 202
Advenchen Laboratories, LLC 203
Onconova Therapeutics, Inc 204
MolMed S.p.A. 205
Immunotope, Inc. 206
Esperance Pharmaceuticals, Inc. 207
Omeros Corporation 208
Bolder Biotechnology, Inc. 209
ImmunoVaccine Technologies Inc. 210
Welichem Biotech Inc. 211
Angstrom Pharmaceuticals, Inc. 212
Cellceutix Corporation 213
PharmaMar, S.A. 214
TVAX Biomedical, LLC 215
Quintessence Biosciences, Inc. 216
VentiRx Pharmaceuticals, Inc. 217
AmpliMed Corporation 218
Tigris Pharmaceuticals, Inc. 219
Viventia Biotechnologies Inc. 220
TRACON Pharmaceuticals, Inc. 221
Domainex Ltd. 222
Anaphore, Inc. 223
Oncolix, Inc. 224
OHR Pharmaceutical Inc. 225
Cancer Therapeutics CRC Pty Ltd 226
Aragon Pharmaceuticals, Inc. 227
RECEPTA Biopharma S.A. 228
Bioo Therapeutics 229
Kyowa Hakko Kirin Pharma, Inc. 230
Vaxonco 231
Sentinel Oncology Limited 232
VectorLogics, Inc. 233
DEKK-TEC, Inc. 234
ISA Pharmaceuticals B.V. 235
Gradalis Inc. 236
Oncozyme Pharma Inc. 237
Ovarian Cancer – Therapeutics Assessment 238
Assessment by Monotherapy Products 238
Assessment by Combination Products 239
Assessment by Route of Administration 240
Assessment by Molecule Type 242
Drug Profiles 244
trebananib - Drug Profile 244
Product Description 244
Mechanism of Action 244
R&D Progress 244
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 270
Product Description 270
Mechanism of Action 270
R&D Progress 270
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 272
Product Description 272
Mechanism of Action 272
R&D Progress 272
Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 274
Product Description 274
Mechanism of Action 274
R&D Progress 274
Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 276
Product Description 276
Mechanism of Action 276
R&D Progress 276
pazopanib hydrochloride - Drug Profile 354
Product Description 354
Mechanism of Action 354
R&D Progress 354
erlotinib hydrochloride - Drug Profile 356
Product Description 356
Mechanism of Action 356
R&D Progress 356
Paclitaxel + AZD0530 - Drug Profile 358
Product Description 358
Mechanism of Action 358
R&D Progress 358
Cisplatin + Cyclophosphamide + Tamoxifen - Drug Profile 359
Product Description 359
Mechanism of Action 359
R&D Progress 359
AMG 386 + Carboplatin + Paclitaxel - Drug Profile 378
Product Description 378
Mechanism of Action 378
R&D Progress 379
Pegylated Liposomal Doxorubicin + Trabectedin - Drug Profile 380
Product Description 380
Mechanism of Action 380
R&D Progress 380
MORAb-003 + Carboplatin + Paclitaxel - Drug Profile 381
Product Description 381
Mechanism of Action 381
R&D Progress 381
Ovarian Cancer Therapeutics – Drug Profile Updates 383
Ovarian Cancer Therapeutics – Discontinued Products 399
Ovarian Cancer Therapeutics - Dormant Products 405
Ovarian Cancer – Product Development Milestones 440
Featured News & Press Releases 440
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Results Of MM-111 At European Society for Medical Oncology 2012 440
Oct 01, 2012: MethylGene Presents Clinical Data On MGCD265 At European Society For Medical Oncology 2012 Congress 441
Sep 30, 2012: Lurbinectedin Shows Activity In Patients With Platinum-Resistant/Refractory Ovarian Cancer 442
Sep 20, 2012: Roche's Avastin Obtains Positive Opinion From CHMP To Treat Various Cancers 443
Sep 18, 2012: Aprea Announces Positive Data From Clinical Phase I/II Study With APR-246 In Patients With Advanced Cancers 444
Sep 18, 2012: Merrimack Pharma To Present Preliminary Clinical Data On MM-121 At ESMO 2012 Congress 444
Sep 07, 2012: PharmaMar's Ovarian Cancer Drug Receives Positive Opinion For Orphan Drug Designation From EMA's COMP 445
Sep 06, 2012: EntreMed Announces Publication Of Phase II Date Of ENMD-2076 In European Journal Of Cancer 445
Sep 05, 2012: Coronado Biosciences Receives First US Patent Covering CNDO-109 446
Aug 29, 2012: PharmaMar Receives Orphan Drug Designation From FDA For PM-01183 447
Appendix 448
Methodology 448
Coverage 448
Secondary Research 448
Primary Research 448
Expert Panel Validation 448
Contact Us 449
Disclaimer 449

List of Tables
Number of Products Under Development for Ovarian Cancer, H2 2012 24
Products under Development for Ovarian Cancer – Comparative Analysis, H2 2012 25
Number of Products under Development by Companies, H2 2012 27
Number of Products under Development by Companies, H2 2012 (Contd..1) 28
Number of Products under Development by Companies, H2 2012 (Contd..2) 29
Number of Products under Development by Companies, H2 2012 (Contd..3) 30
Number of Products under Development by Companies, H2 2012 (Contd..4) 31
Number of Products under Development by Companies, H2 2012 (Contd..5) 32
Number of Products under Development by Companies, H2 2012 (Contd..6) 33
Number of Products under Development by Companies, H2 2012 (Contd..7) 34
Number of Products under Development by Companies, H2 2012 (Contd..8) 35
Number of Products under Development by Companies, H2 2012 (Contd..9) 36
Number of Products under Development by Companies, H2 2012 (Contd..10) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 48
Comparative Analysis by Late Stage Development, H2 2012 49
Comparative Analysis by Mid Clinical Stage Development, H2 2012 50
Comparative Analysis by Early Clinical Stage Development, H2 2012 51
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 52
Products under Development by Companies, H2 2012 53
Products under Development by Companies, H2 2012 (Contd..1) 54
Products under Development by Companies, H2 2012 (Contd..2) 55
Products under Development by Companies, H2 2012 (Contd..3) 56
Products under Development by Companies, H2 2012 (Contd..4) 57
Products under Development by Companies, H2 2012 (Contd..5) 58
Products under Development by Companies, H2 2012 (Contd..6) 59
Products under Development by Companies, H2 2012 (Contd..7) 60
Products under Development by Companies, H2 2012 (Contd..8) 61
Products under Development by Companies, H2 2012 (Contd..9) 62
Products under Development by Companies, H2 2012 (Contd..10) 63
Products under Development by Companies, H2 2012 (Contd..11) 64
Products under Development by Companies, H2 2012 (Contd..12) 65
Products under Development by Companies, H2 2012 (Contd..13) 66
Products under Development by Companies, H2 2012 (Contd..14) 67
Products under Development by Companies, H2 2012 (Contd..15) 68
Products under Investigation by Universities/Institutes, H2 2012 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 90
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 91
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 92
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 93
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 94
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 95
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 96
Bristol-Myers Squibb Company, H2 2012 97
Johnson & Johnson, H2 2012 98
Boehringer Ingelheim GmbH, H2 2012 99
F. Hoffmann-La Roche Ltd., H2 2012 100
Abbott Laboratories, H2 2012 101
AlphaRx, Inc., H2 2012 102
Amgen Inc., H2 2012 103
Sanofi-Aventis, H2 2012 104
AstraZeneca PLC, H2 2012 105
Eli Lilly and Company, H2 2012 106
Viralytics Ltd., H2 2012 107
GlaxoSmithKline plc, H2 2012 108
Bioniche Life Sciences, Inc., H2 2012 109
Tekmira Pharmaceuticals Corp., H2 2012 110
Genentech, Inc., H2 2012 111
Nektar Therapeutics, H2 2012 112
Bavarian Nordic A/S, H2 2012 113
Daiichi Sankyo Company, Ltd, H2 2012 114
Merck & Co., Inc., H2 2012 115
AbGenomics International, Inc., H2 2012 116
FASgen, Inc., H2 2012 117
Oxford BioMedica plc, H2 2012 118
Generex Biotechnology Corporation, H2 2012 119
Amorfix Life Sciences Ltd., H2 2012 120
MediGene AG, H2 2012 121
Prolexys Pharmaceuticals, Inc., H2 2012 122
Aposense Ltd., H2 2012 123
ZIOPHARM Oncology, Inc., H2 2012 124
Millennium Pharmaceuticals, Inc., H2 2012 125
Samyang Corporation, H2 2012 126
Aphios Corporation, H2 2012 127
Astellas Pharma Inc., H2 2012 128
Eisai Co., Ltd., H2 2012 129
ImmunoGen, Inc., H2 2012 130
OSI Pharmaceuticals, Inc., H2 2012 131
Sunesis Pharmaceuticals, Inc., H2 2012 132
Cell Therapeutics, Inc., H2 2012 133
Santaris Pharma A/S, H2 2012 134
Exelixis, Inc., H2 2012 135
Menarini Group, H2 2012 136
Alfacell Corporation, H2 2012 137
Celgene Corporation, H2 2012 138
Onyx Pharmaceuticals, Inc., H2 2012 139
Bayer AG, H2 2012 140
Merck KGaA, H2 2012 141
Access Pharmaceuticals, Inc., H2 2012 142
Advaxis, Inc., H2 2012 143
Neogenix Oncology Corporation, H2 2012 144
EntreMed, Inc., H2 2012 145
Hana Biosciences, Inc., H2 2012 146
Celldex Therapeutics, Inc., H2 2012 147
ValiRx Plc, H2 2012 148
AEterna Zentaris Inc., H2 2012 149
ImmunoCellular Therapeutics, Ltd., H2 2012 150
Lorus Therapeutics Inc, H2 2012 151
Marshall Edwards, Inc., H2 2012 152
AVAX Technologies, Inc., H2 2012 153
Basilea Pharmaceutica Ltd., H2 2012 154
Bionomics Limited, H2 2012 155
Novogen Limited, H2 2012 156
Cleveland BioLabs, Inc., H2 2012 157
Oncolytics Biotech Inc., H2 2012 158
OXiGENE, Inc., H2 2012 159
Critical Outcome Technologies Inc., H2 2012 160
ADVENTRX Pharmaceuticals, H2 2012 161
Allos Therapeutics, Inc, H2 2012 162
Alnylam Pharmaceuticals, Inc, H2 2012 163
Telik, Inc., H2 2012 164
TopoTarget A/S, H2 2012 165
Poniard Pharmaceuticals, Inc., H2 2012 166
Oncogenex Pharmaceuticals, Inc., H2 2012 167
Dendreon Corporation, H2 2012 168
Prima BioMed Limited, H2 2012 169
Progen Pharmaceuticals Limited, H2 2012 170
TTY Biopharm Company Limited, H2 2012 171
Innocell Corporation, H2 2012 172
PharmaGap Inc., H2 2012 173
Quest PharmaTech Inc., H2 2012 174
Synta Pharmaceuticals Corp., H2 2012 175
Oasmia Pharmaceutical AB, H2 2012 176
RXi Pharmaceuticals Corporation, H2 2012 177
Rexahn Pharmaceuticals, Inc., H2 2012 178
MabVax Therapeutics, Inc., H2 2012 179
Morphotek, Inc., H2 2012 180
Cancer Research Technology Limited, H2 2012 181
Avanti Therapeutics, H2 2012 182
Chipscreen Biosciences Ltd, H2 2012 183
Supratek Pharma Inc., H2 2012 184
GANYMED Pharmaceuticals AG, H2 2012 185
Nerviano Medical Sciences S.r.l., H2 2012 186
Glycotope GmbH, H2 2012 187
TRION Pharma GmbH, H2 2012 188
BioNumerik Pharmaceuticals, Inc., H2 2012 189
Cerulean Pharma, Inc., H2 2012 190
Heat Biologics, Inc., H2 2012 191
MacroGenics, Inc., H2 2012 192
Boston Biomedical, Inc., H2 2012 193
Azaya Therapeutics, Inc., H2 2012 194
CanBas Co., Ltd., H2 2012 195
Merrimack Pharmaceuticals, Inc., H2 2012 196
Spirogen Ltd., H2 2012 197
Neotropix, Inc., H2 2012 198
Conatus Pharmaceuticals Inc., H2 2012 199

List of Figures
Number of Products under Development for Ovarian Cancer, H2 2012 24
Products under Development for Ovarian Cancer – Comparative Analysis, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 38
Late Stage Products, H2 2012 49
Mid Clinical Stage Products, H2 2012 50
Early Clinical Stage Products, H2 2012 51
Discovery and Pre-Clinical Stage Products, H2 2012 52
Assessment by Monotherapy Products, H2 2012 238
Assessment by Combination Products, H2 2012 239
Assessment by Route of Administration, H2 2012 240
Assessment by Stage and Route of Administration, H2 2012 241
Assessment by Molecule Type, H2 2012 242
Assessment by Stage and Molecule Type, H2 2012 243

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos